Literature DB >> 24756569

Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting report.

Christoph Heesen1, Jared Bruce2, Peter Feys3, Jaume Sastre-Garriga4, Alessandra Solari5, Lina Eliasson6, Vicki Matthews7, Bettina Hausmann8, Amy Perrin Ross9, Miho Asano10, Kaisa Imonen-Charalambous11, Sascha Köpke12, Wendy Clyne13, Paul Bissell14.   

Abstract

BACKGROUND: Adherence to medical interventions is a global problem. With an increasing amount of partially effective but expensive drug treatments adherence is increasingly relevant in multiple sclerosis (MS). Perceived lack of efficacy and side effects as well as neuropsychiatric factors such as forgetfulness, fatigue and depression are major determinants. However, research on adherence to behavioural interventions as part of rehabilitative interventions has only rarely been studied.
METHODS: In a one-day meeting health researchers as well as patient representatives and other stakeholders discussed adherence issues in MS and developed a general draft research agenda within a focus group session.
RESULTS: The focus group addressed four major areas: (1) focussing patients and their informal team; (2) studying health care professionals; (3) comparing practice across cultures; and (4) studying new adherence interventions.
CONCLUSIONS: A focus on patient preferences as well as a non-judgmental discussion on adherence issues with patients should be at the core of adherence work.
© The Author(s), 2014.

Entities:  

Keywords:  Disease-modifying therapies; adherence; multiple sclerosis; rehabilitation

Mesh:

Year:  2014        PMID: 24756569     DOI: 10.1177/1352458514531348

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  7 in total

1.  [Current immunotherapy of multiple sclerosis].

Authors:  F Paul; K Ruprecht
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

2.  Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence.

Authors:  Jared M Bruce; Amanda S Bruce; Sharon Lynch; Joanie Thelen; Seung-Lark Lim; Julia Smith; Delwyn Catley; Derek D Reed; David P Jarmolowicz
Journal:  Psychopharmacology (Berl)       Date:  2018-09-22       Impact factor: 4.530

3.  Adherence to behavioural interventions in multiple sclerosis: Follow-up meeting report (AD@MS-2).

Authors:  Christoph Heesen; Jared Bruce; Robert Gearing; Rona Moss-Morris; John Weinmann; Paivi Hamalainen; Robert Motl; Ulrik Dalgas; Daphne Kos; Franceso Visioli; Peter Feys; Alessandra Solari; Marcia Finlayson; Lina Eliasson; Vicki Matthews; Angeliki Bogossian; Katrin Liethmann; Sascha Köpke; Paul Bissell
Journal:  Mult Scler J Exp Transl Clin       Date:  2015-05-12

4.  Perspectives From Persons With Multiple Sclerosis for a Comprehensive Real-World Change Therapy for Mobility.

Authors:  Victor W Mark; Ritalinda D'Andrea Lee; Edward Taub; Gitendra Uswatte
Journal:  Arch Rehabil Res Clin Transl       Date:  2021-11-12

5.  A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva® PSP.

Authors:  Serena Barello; Damiano Paolicelli; Roberto Bergamaschi; Salvatore Cottone; Alessandra D'Amico; Viviana Annibali; Andrea Paolillo; Caterina Bosio; Valentina Panetta; Guendalina Graffigna
Journal:  Front Psychol       Date:  2022-08-24

6.  Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study.

Authors:  Andrea Zimmer; Michael Coslovsky; Ivo Abraham; Bernhard F Décard
Journal:  Patient Prefer Adherence       Date:  2017-10-20       Impact factor: 2.711

7.  The Use of Digital and Remote Communication Technologies as a Tool for Multiple Sclerosis Management: Narrative Review.

Authors:  Martin Marziniak; Giampaolo Brichetto; Peter Feys; Uta Meyding-Lamadé; Karen Vernon; Sven G Meuth
Journal:  JMIR Rehabil Assist Technol       Date:  2018-04-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.